bevacizumab,atezolizumab,tislelizumab,Sorafenib
roche,beigene,Novartis,Bayer
[]
positive hcc rationale study with tiselizumab again brings up question about contribution of bev in atezo/bev regimen. #hcc #gi23
Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Passionate about clinical research, education and pt-prov communication. #gicancer #meded